Vanguard Renewables announces revolutionary partnership with AstraZeneca to decarbonize United States medicines manufacturing

In a first-of-its-kind collaboration, AstraZeneca (AZN) is partnering with Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of its sites in the United States by the end of 2026.

Brand Provided | By Vanguard Renewables | Published 1 year ago | About a 2 minute read

From June 2023, AstraZeneca will begin purchasing RNG produced by Vanguard Renewables for its Newark Campus in Delaware, where the Company packages 26 medicines for distribution across the U.S. and makes medicine formulations for global supply. By 2026, this collaboration will enable as much as 650,000 million British thermal units (MMBtu), or 190,500 megawatt hours (MWh), per year of RNG to be used across AstraZeneca’s U.S. sites, equivalent to the energy required to heat more than 17,800 U.S. homes for a year.

Pam Cheng, Executive Vice President of Global Operations & IT and Chief Sustainability Officer at AstraZeneca, said: “We recognize the interconnection between the health of people and the planet, and are committed to driving deep decarbonization across our operations and value chain. Our innovative partnership with Vanguard Renewables in the U.S. is an illustration of how we are collaborating at scale to deliver sustainable science and medicines, as part of the transition to net zero health systems and a circular economy.”

AstraZeneca is taking a science-led, patient-centric approach to deliver improved health outcomes with a lower environmental footprint. As heat and power are critical to the manufacture of medicines, the decarbonization of healthcare requires access to clean sources of heat, such as renewable natural gas. This new partnership with Vanguard Renewables is an important milestone in delivering emissions reductions in line with AstraZeneca’s flagship Ambition Zero Carbon program. The Company is on track to reduce greenhouse gas (GHG) emissions from its global operations (Scope 1 and 2) by 98% by 2026 from a 2015 baseline, and by 2030, AstraZeneca aims to halve its entire value chain footprint on the way to becoming science-based net zero by 2045 at the latest. The use of RNG at AstraZeneca sites in the U.S. will further enable the company’s transition to 100 percent renewable energy for heat and power.

Read full story here.